Axial’s Vice President, Head of Preclinical R&D, Becca Senter is presenting tomorrow at the 2024 AD/PD - Advances in Science & Therapy International Conference on #Alzheimers and #Parkinsons Disease in Lisbon, Portugal. Learn more: https://adpd.kenes.com/ #ADPD2024
Axial Therapeutics, Inc.
Biotechnology Research
Waltham, MA 3,406 followers
Clinical-stage CNS bio-pharmaceutical company focused on small molecule therapies
About us
Axial Therapeutics™ is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central nervous system (CNS) disorders. The company is leveraging its expertise in the gut-brain axis and its unique drug development platform to advance novel therapies that have the potential to transform the treatment paradigm in neurodegenerative diseases.
- Website
-
http://www.axialtx.com
External link for Axial Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Waltham, MA
- Type
- Privately Held
- Founded
- 2016
- Specialties
- Neurological disorders and diseases, autism, parkinson's disease, gut-brain axis, and small molecule
Locations
-
Primary
Get directions
9 Fourth Avenue
Waltham, MA 02451, US
Employees at Axial Therapeutics, Inc.
-
Radka Graf
Director, Preclinical Development and Operations at Axial Therapeutics, Inc.
-
A. Stewart Campbell
Chief Executive Officer at Axial Therapeutics, Inc.
-
Kate Zeghibe
Biotechnology and Pharmaceutical Industry | Strategy | Partnering | Portfolio & Program Management | Harvard & Tuck
-
Jennifer Lau
Principal Scientist at Axial Therapeutics
Updates
-
At Axial, we are committed to ensuring the safety and security of our community and potential candidates. Recently, we have been made aware of individuals posing as Axial employees to recruit and offer employment to potential candidates. Axial is not currently hiring and we urge you to exercise caution and verify the authenticity of the communication before proceeding. Please do not hesitate to reach out to us directly at [email protected] for confirmation before engaging further with any recruitment-related communications.
-
This week at the 2024 #BiotechShowcase, Axial's CEO A. Stewart Campbell presented on our mission to advance a pipeline of gut-targeted small molecule therapies in areas of significant unmet patient need including autism spectrum disorder and Parkinson’s disease. Learn more: www.axialtx.com
-
-
Axial Therapeutics, Inc. reposted this
Axial’s CEO A. Stewart Campbell will give a corporate presentation at the 2024 #BiotechShowcase in San Francisco today at 10:30 a.m. PT. Learn more: https://lnkd.in/dSFVcVM #BioWeekSF #JPM24
-
-
Axial’s CEO A. Stewart Campbell will give a corporate presentation at the 2024 #BiotechShowcase in San Francisco today at 10:30 a.m. PT. Learn more: https://lnkd.in/dSFVcVM #BioWeekSF #JPM24
-
-
Today at the Longwood Healthcare Leaders San Francisco CEO Conference, A. Stewart Campbell, PhD, Axial’s CEO, will participate in a panel discussion, “Advancing Research into the Clinic,” at 1:30 p.m. PT. Learn more: https://lnkd.in/esNkzCWY #LongwoodHealthcareLeaders #BioWeekSF #JPM24
-
-
Next week, Axial’s CEO, A. Stewart Campbell, PhD, will participate in the Longwood Healthcare Leaders CEO Conference and the 2024 Biotech Showcase. We look forward to sharing more about our mission to develop #microbiome therapeutics! https://bit.ly/48sPuZm #BioWeekSF #JPM24 #BiotechShowcase
-
-
Happy Holidays from the Axial team! Wishing everyone a restful, happy and healthy holiday season! #HappyHolidays #SeasonsGreetings
-
-
Today, Axial’s VP, Head of Preclinical Research and Development Becca Senter, PhD, is presenting on the development of AX-5006 for the treatment of #ParkinsonsDisease and joining a panel discussion on emerging therapeutic modalities for #microbiome modulation at Microbiome Connect USA 2023 in Boston. Learn more: https://bit.ly/3QRZ7dw #MicrobiomeConnect #MicrobiomeConnectUSA
-
-
Next week, Becca Senter, PhD, Axial’s VP, Head of Preclinical Research and Development will present on the development of AX-5006 for the treatment of #ParkinsonsDisease and participate in a panel on emerging therapeutic modalities for #microbiome modulation at Microbiome Connect USA 2023, Nov. 14-16 in Boston. Learn more: https://bit.ly/3QRZ7dw #MicrobiomeConnect #MicrobiomeConnectUSA
-